Published in Neurology on May 15, 2007
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology (2011) 2.61
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology (2011) 2.35
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain (2009) 2.05
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
APOE genotype modulates proton magnetic resonance spectroscopy metabolites in the aging brain. Biol Psychiatry (2013) 1.95
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Beta-amyloid, blood vessels, and brain function. Stroke (2009) 1.89
Brain amyloid and cognition in Lewy body diseases. Mov Disord (2012) 1.87
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86
CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology (2009) 1.85
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging (2014) 1.80
Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis (2010) 1.73
Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology (2009) 1.70
β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage (2010) 1.68
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol (2012) 1.64
The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging (2010) 1.63
Differential FDDNP PET patterns in nondemented middle-aged and older adults. Am J Geriatr Psychiatry (2009) 1.62
Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement (2011) 1.54
Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics (2016) 1.53
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 1.51
Longitudinal changes in cortical thickness associated with normal aging. Neuroimage (2010) 1.49
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain (2008) 1.47
White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol (2013) 1.47
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Amyloid pathology and axonal injury after brain trauma. Neurology (2016) 1.43
Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol (2009) 1.42
Structural and functional imaging in parkinsonian syndromes. Radiographics (2014) 1.41
Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain (2013) 1.40
Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging (2011) 1.40
Neuroimaging Biomarkers and Impaired Olfaction in Cognitively Normal Individuals. Ann Neurol (2017) 1.39
Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging (2011) 1.37
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Antemortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging (2010) 1.37
Brain aging, Alzheimer's disease, and mitochondria. Biochim Biophys Acta (2011) 1.36
The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype. Alzheimers Dement (2011) 1.35
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (2013) 1.34
Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology (2012) 1.33
Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol (2011) 1.32
Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain (2015) 1.31
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement (2011) 1.30
APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol (2010) 1.30
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. J Med Chem (2010) 1.28
Amyloid imaging of Lewy body-associated disorders. Mov Disord (2010) 1.27
Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med (2009) 1.27
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.25
Beta-amyloid deposition and the aging brain. Neuropsychol Rev (2009) 1.25
The early neuropsychological and behavioral characteristics of frontotemporal dementia. Neuropsychol Rev (2008) 1.25
The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction. JAMA Neurol (2013) 1.25
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol (2010) 1.24
Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain (2011) 1.23
NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest (2009) 1.23
Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? J Nucl Med (2008) 1.22
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 1.21
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One (2013) 1.21
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging (2010) 1.19
Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol (2007) 1.19
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging (2012) 1.19
Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. Transl Psychiatry (2013) 1.19
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage (2013) 1.17
Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging (2011) 1.17
Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging (2008) 1.17
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol (2013) 1.17
Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging (2014) 1.17
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol (2012) 1.16
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 17.08
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Microbial complexes in subgingival plaque. J Clin Periodontol (1998) 15.90
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med (1999) 9.78
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia (2009) 6.55
Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med (1996) 6.49
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J (1985) 6.24
Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Proc Natl Acad Sci U S A (1986) 6.16
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer (2005) 6.06
Effect of total allelic relationship on accuracy of evaluation and response to selection. J Anim Sci (1997) 5.79
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol (1979) 5.53
Rapid induction of Alzheimer A beta amyloid formation by zinc. Science (1994) 5.34
Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell (1989) 4.99
Body mass index and cardiovascular disease in the Asia-Pacific Region: an overview of 33 cohorts involving 310 000 participants. Int J Epidemiol (2004) 4.67
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 4.42
Activation of memory circuits during cue-elicited cocaine craving. Proc Natl Acad Sci U S A (1996) 4.31
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci U S A (1992) 4.08
Sexual abuse in a national survey of adult men and women: prevalence, characteristics, and risk factors. Child Abuse Negl (1990) 3.96
Golgi tubule traffic and the effects of brefeldin A visualized in living cells. J Cell Biol (1997) 3.91
Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A (1999) 3.91
Evaluation of two school smoking education programmes under normal classroom conditions. BMJ (1993) 3.83
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell (1996) 3.81
Chromosomal location of genes regulating resistance to bacteriophage in Bacillus subtilis. J Bacteriol (1969) 3.74
Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet (2008) 3.65
Acrasin, Acrasinase, and the sensitivity to acrasin in Dictyostelium discoideum. Dev Biol (1969) 3.56
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
Undergraduate research. Genomics Education Partnership. Science (2008) 3.45
Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J Mol Biol (1991) 3.33
A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology (1988) 3.28
Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med (1989) 3.24
Asia Pacific consensus recommendations for colorectal cancer screening. Gut (2008) 3.19
A three-item scale for the early prediction of stroke recovery. Lancet (2001) 3.15
Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A (1990) 3.13
Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem (1996) 3.10
Discriminating between different modes of inheritance in genetic disease. Clin Genet (1971) 3.10
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
Training family doctors to recognise psychiatric illness with increased accuracy. Lancet (1980) 3.09
Women's health: potential for better coordination of services. Genitourin Med (1991) 2.99
Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. Nat Med (1997) 2.95
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology (2010) 2.92
Charybdotoxin block of single Ca2+-activated K+ channels. Effects of channel gating, voltage, and ionic strength. J Gen Physiol (1988) 2.87
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care (2004) 2.77
Health spending growth up in 1999; faster growth expected in the future. Health Aff (Millwood) (2001) 2.77
Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology (1998) 2.70
"Checkerboard" DNA-DNA hybridization. Biotechniques (1994) 2.70
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry (2001) 2.70
A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant (1993) 2.69
11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology (2007) 2.65
Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest (1991) 2.65
Impaired sucrose-induction mutants reveal the modulation of sugar-induced starch biosynthetic gene expression by abscisic acid signalling. Plant J (2001) 2.61
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia (2008) 2.58
Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol (2003) 2.57
Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain (2006) 2.54
Accuracy of the estimated prevalence of obesity from self reported height and weight in an adult Scottish population. J Epidemiol Community Health (2000) 2.50
Subacute spongiform encephalopathy (Creutzfeldt-Jakob disease). The nature and progression of spongiform change. Brain (1978) 2.49
PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry (1999) 2.48
Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res (1991) 2.46
Concordance in twins: methods and interpretation. Am J Hum Genet (1974) 2.45
Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A (1986) 2.42
Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet (2008) 2.42
Heteroplasmic mtDNA mutation (T----G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. Am J Hum Genet (1992) 2.41
Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys (1992) 2.37
Heritability of liability and concordance in monozygous twins. Ann Hum Genet (1970) 2.35
Ascertainment and prevention of genetic disease. Br Med J (1970) 2.33
Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. J Nucl Med (2000) 2.33
Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev (2008) 2.32
By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart (2005) 2.32
Packaging of prions into exosomes is associated with a novel pathway of PrP processing. J Pathol (2007) 2.31
Community outbreak of psittacosis in a rural Australian town. Lancet (1998) 2.30
Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med (1999) 2.30
Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem (1999) 2.30
The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I) Science (1996) 2.29
Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell (2001) 2.29